1. Home
  2. SOWG vs NNVC Comparison

SOWG vs NNVC Comparison

Compare SOWG & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sow Good Inc.

SOWG

Sow Good Inc.

HOLD

Current Price

$3.97

Market Cap

25.4M

ML Signal

HOLD

NNVC

NanoViricides Inc.

HOLD

Current Price

$1.35

Market Cap

21.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOWG
NNVC
Founded
2010
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.4M
21.2M
IPO Year
2011
2008

Fundamental Metrics

Financial Performance
Metric
SOWG
NNVC
Price
$3.97
$1.35
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
148.3K
924.1K
Earning Date
05-15-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
10.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.10
$0.85
52 Week High
$4.45
$2.23

Technical Indicators

Market Signals
Indicator
SOWG
NNVC
Relative Strength Index (RSI) 86.28 48.03
Support Level $0.48 $1.35
Resistance Level N/A $1.48
Average True Range (ATR) 0.40 0.12
MACD 0.20 -0.03
Stochastic Oscillator 81.23 33.96

Price Performance

Historical Comparison
SOWG
NNVC

About SOWG Sow Good Inc.

Sow Good Inc is engaged in manufacturing and marketing freeze-dried fruits, vegetables, snacks, smoothies, and soups. The company also sells gluten-free products under the Sow Good brand. The company is developing a freeze-dried candy market and snack manufacturing to provide consumers with flavorful freeze-dried treats. The company operates in one reportable segment, reflecting its capital-light business model under which it earns proceeds from the sale of freeze-dried candy products.

About NNVC NanoViricides Inc.

Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.

Share on Social Networks: